Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

  • Print
Details
Category: Impact Factor 5
Hits: 3507

Clinical Cancer Research

1 juillet 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.